Neuren Pharmaceuticals Limited (ASX:NEU)
Australia · Delayed Price · Currency is AUD 17.51
-0.03 (-0.17%)
Jul 16, 2026, 4:10 PM AEST
Neuren Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Neuren Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $24.33. The average 1-year stock price forecast is 38.95% higher than the current stock price, while the lowest is $19.10 (+9.08%) and the highest is $29.00 (+65.62%).
Price Target: $24.33 (+38.95%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Neuren Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Macquarie No rating | Macquarie | Buy Maintains $19.10 | Buy | Maintains | $19.10 | +9.08% | Jun 30, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $24.00 | Buy | Maintains | $24.00 | +37.06% | Jun 30, 2026 |
| Bell Potter | Bell Potter | Buy Maintains $22.00 → $23.50 | Buy | Maintains | $22.00 → $23.50 | +34.21% | Jun 29, 2026 |
| Jefferies | Jefferies | Buy Maintains $27.00 | Buy | Maintains | $27.00 | +54.20% | Feb 6, 2026 |
| Petra Capital | Petra Capital | Buy Maintains $29.96 | Buy | Maintains | $29.96 | +71.10% | Feb 5, 2026 |
Financial Forecast
Revenue This Year
115.24M
from 64.65M
Increased by 78.25%
Revenue Next Year
159.15M
from 115.24M
Increased by 38.11%
EPS This Year
0.29
from 0.23
Increased by 22.54%
EPS Next Year
0.56
from 0.29
Increased by 95.63%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is AUD.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 137.2M | ||
| Avg | 115.2M | ||
| Low | 71.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 112.3% | ||
| Avg | 78.2% | ||
| Low | 10.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.48 | ||
| Avg | 0.29 | ||
| Low | 0.16 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 106.1% | ||
| Avg | 22.5% | ||
| Low | -31.2% |